Achillion study results to be presented at EASL conference

Achillion Pharmaceuticals Inc. today announced that the interim results of its ongoing phase 2a study, conducted by Alios BioPharma, part of the Janssen Pharmaceutical Companies, will be presented at the European Association for the Study of the Liver (EASL) Special Conference taking place Sept. 23-24 in Paris, France.

The study was developed to confirm the necessary dose and period of treatment for an all-oral blended routine that is comprised of odalasvir (ODV) and AL-335 with or without simeprevir (SMV) for treatment lasting the span of six or eight weeks for patients who have the genotype 1 (GT1) chronic hepatitis C virus (HCV) infection that have yet to receive treatment.

“We are delighted by the significant progress Janssen has made in advancing the all-oral, short-duration treatment regimen of odalasvir, AL-335 and simeprevir and are impressed with the Phase 2a study results being presented,” Achillion President and CEO Dr. Milind Deshpande said. “Based on these interim results, Janssen plans to advance a phase 2b program for the triple combination to further understand the potential of this 3DAA drug combination to shorten the duration of treatment for patients suffering from HCV. Despite recent therapeutic advances, we believe there remains a significant unmet need in addressing the global burden of hepatitis C virus in those living with the disease.”